Literature DB >> 31711634

Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study).

Gregory Y H Lip1, Flemming Skjøth2, Peter Brønnum Nielsen3, Torben Bjerregaard Larsen3.   

Abstract

A simple clinical score, C2HEST (C2: CAD/COPD [1 point each]; H: Hypertension; E: Elderly [Age ≥75, doubled]; S: Systolic HF [doubled]; T: Thyroid disease [hyperthyroidism]) has been proposed to predict incident atrial fibrillation (AF), with good discrimination and internal calibration. To define high-risk patients at particular age strata for incident AF in a nationwide population cohort, who could potentially be targeted for AF screening, we used a nationwide cohort study of all Danish citizen aged ≥65 years to evaluate the performance of the C2HEST score. "High risk" subjects at age 65, 70, and 75 had 5-year risks of new onset AF of 11.8%, 14.2% and 13.6%, respectively, and the corresponding event rates were 2.99, 3.67, and 3.38 per 100 person years, respectively. Associated hazard ratios (HR) were 4.08 (95% confidence interval [CI] 3.84 to 4.34), 3.80 (95% CI: 3.68 to 3.92) and 2.17 (95% CI: 2.13 to 2.22), respectively compared with the lowest risk strata within age category. At all age cohorts, the greatest risk component of the C2HEST score on multivariable analysis was by having 2 points for C (C2), that is both CAD and COPD followed by systolic heart failure (S) both with HRs up to 2.0. CAD or COPD alone (C1) or hypertension (H) were associated with increased risk of new onset AF corresponding to HR between 1.44 and 1.64. In conclusion, this nationwide population cohort addresses the question on clinical risk prediction for new onset AF in a population at different age strata, whereby the C2HEST score may help in identifying those at 'high risk' of new onset AF at 3 distinct age cohorts (65, 70, and 75 years). A high risk C2HEST score stratum was associated with a greater risk of new onset AF. These patients could be considered for more intensive efforts for screening and detection of incident AF.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31711634     DOI: 10.1016/j.amjcard.2019.09.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Population-Based Screening or Targeted Screening Based on Initial Clinical Risk Assessment for Atrial Fibrillation: A Report from the Huawei Heart Study.

Authors:  Yutao Guo; Hao Wang; Hui Zhang; Yundai Chen; Gregory Y H Lip
Journal:  J Clin Med       Date:  2020-05-15       Impact factor: 4.241

2.  C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial.

Authors:  Weihao Liang; Yuzhong Wu; Gregory Y H Lip; Wengen Zhu; Chen Liu; Ruicong Xue; Zexuan Wu; Dexi Wu; Jiangui He; Yugang Dong
Journal:  BMC Med       Date:  2021-02-18       Impact factor: 8.775

3.  Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the C2HEST Score: The West Birmingham Atrial Fibrillation Project.

Authors:  Yan-Guang Li; Daniele Pastori; Kazuo Miyazawa; Farhan Shahid; Gregory Y H Lip
Journal:  J Am Heart Assoc       Date:  2021-03-05       Impact factor: 5.501

Review 4.  Identifying Atrial Fibrillation Mechanisms for Personalized Medicine.

Authors:  Brototo Deb; Prasanth Ganesan; Ruibin Feng; Sanjiv M Narayan
Journal:  J Clin Med       Date:  2021-12-01       Impact factor: 4.241

Review 5.  C2HEST score for atrial fibrillation risk prediction models: a Diagnostic Accuracy Tests meta-analysis.

Authors:  Habib Haybar; Kimia Shirbandi; Fakher Rahim
Journal:  Egypt Heart J       Date:  2021-12-04

6.  Impact of COPD or Asthma on the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Zhengbiao Xue; Siyu Guo; Xiao Liu; Jianyong Ma; Wengen Zhu; Yue Zhou; Fuwei Liu; Jun Luo
Journal:  Front Cardiovasc Med       Date:  2022-04-11

7.  The performance of five models compared with atrial high rate episodes predicts new atrial fibrillation after cardiac implantable electronic devices implantation.

Authors:  Ju-Yi Chen; Tse-Wei Chen; Wei-Da Lu
Journal:  Ann Noninvasive Electrocardiol       Date:  2022-06-04       Impact factor: 1.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.